RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Travere Therapeutics Stock

Travere Therapeutics EBIT 2024

Travere Therapeutics EBIT

-272.7 M USD

Ticker

TVTX

ISIN

US89422G1076

WKN

A2QHYP

In 2024, Travere Therapeutics's EBIT was -272.7 M USD, a -27.62% increase from the -376.74 M USD EBIT recorded in the previous year.

The Travere Therapeutics EBIT history

YEAREBIT (undefined USD)
2029e-
2028e238.39
2027e100.38
2026e-0.78
2025e-151.43
2024e-272.7
2023-376.74
2022-266.5
2021-161.8
2020-79.1
2019-114.9
2018-80.3
2017-47.6
2016-53
2015-46
2014-79.8
2013-24.8
2012-30.3
2011-
2010-
2009-
2008-

Travere Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Travere Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Travere Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Travere Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Travere Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Travere Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Travere Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Travere Therapeutics’s growth potential.

Travere Therapeutics Revenue, EBIT and net profit per share

DateTravere Therapeutics RevenueTravere Therapeutics EBITTravere Therapeutics Net Income
2029e806.19 M undefined0 undefined121.91 M undefined
2028e617.4 M undefined238.39 M undefined48.34 M undefined
2027e494.48 M undefined100.38 M undefined23.68 M undefined
2026e471.04 M undefined-780,983.4 undefined2.66 M undefined
2025e343.44 M undefined-151.43 M undefined-123.96 M undefined
2024e228.73 M undefined-272.7 M undefined-289.15 M undefined
2023145.24 M undefined-376.74 M undefined-111.4 M undefined
2022212 M undefined-266.5 M undefined-278.5 M undefined
2021227.5 M undefined-161.8 M undefined-180.1 M undefined
2020198.3 M undefined-79.1 M undefined-169.4 M undefined
2019175.3 M undefined-114.9 M undefined-146.4 M undefined
2018164.2 M undefined-80.3 M undefined-102.7 M undefined
2017154.9 M undefined-47.6 M undefined-59.7 M undefined
2016133.6 M undefined-53 M undefined-47.9 M undefined
201599.9 M undefined-46 M undefined117.2 M undefined
201428.2 M undefined-79.8 M undefined-110.9 M undefined
20130 undefined-24.8 M undefined-34.6 M undefined
20120 undefined-30.3 M undefined-30.3 M undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined

Travere Therapeutics stock margins

The Travere Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Travere Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Travere Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Travere Therapeutics's sales revenue. A higher gross margin percentage indicates that the Travere Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Travere Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Travere Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Travere Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Travere Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Travere Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Travere Therapeutics Margin History

Travere Therapeutics Gross marginTravere Therapeutics Profit marginTravere Therapeutics EBIT marginTravere Therapeutics Profit margin
2029e92.12 %0 %15.12 %
2028e92.12 %38.61 %7.83 %
2027e92.12 %20.3 %4.79 %
2026e92.12 %-0.17 %0.57 %
2025e92.12 %-44.09 %-36.09 %
2024e92.12 %-119.22 %-126.42 %
202392.12 %-259.4 %-76.7 %
202296.42 %-125.71 %-131.37 %
202197.01 %-71.12 %-79.16 %
202096.92 %-39.89 %-85.43 %
201997.03 %-65.54 %-83.51 %
201896.65 %-48.9 %-62.55 %
201797.68 %-30.73 %-38.54 %
201696.56 %-39.67 %-35.85 %
201597.8 %-46.05 %117.32 %
201497.87 %-282.98 %-393.26 %
201392.12 %0 %0 %
201292.12 %0 %0 %
201192.12 %0 %0 %
201092.12 %0 %0 %
200992.12 %0 %0 %
200892.12 %0 %0 %

Travere Therapeutics Aktienanalyse

What does Travere Therapeutics do?

Travere Therapeutics, Inc is a pharmaceutical company specializing in rare diseases. It was founded in 2019 and is headquartered in San Diego, California. Travere is tirelessly working to develop innovative therapies to improve the lives of patients with rare diseases. History Travere Therapeutics was formed from the merger of Retrophin, Inc and privately held company Censa Pharmaceuticals, Inc. Retrophin was founded in 2011 by Martin Shkreli and had difficulties in developing therapies for rare diseases. Shkreli later left the company and Retrophin focused on developing therapies for multiple rare diseases. In 2019, Retrophin merged with Censa Pharmaceuticals to form Travere Therapeutics, a company solely dedicated to rare diseases. Business Model Travere Therapeutics' business model is to develop innovative therapies for rare diseases that address an unmet medical need. With a strong focus on research and development, the company is working to discover, develop, and market new and life-changing therapies. Travere Therapeutics has a strong pipeline of drugs and medications in various stages of clinical development. This pipeline includes therapies for rare diseases such as nephrotic syndromes, mucopolysaccharidosis, lipid disorders, and others. Divisions Travere Therapeutics specializes in two business areas: pharmaceuticals and diagnostics. Pharmaceutical Business Travere Therapeutics' pharmaceutical business includes researching, developing, and marketing therapies for rare diseases. The company has a strong focus on research and development and has a pipeline of drugs and therapies aimed at improving the lives of patients with rare diseases. Diagnostics Business Travere Therapeutics' diagnostics business focuses on diagnostic tests for rare diseases. The company has partnerships with labs and facilities around the world specializing in diagnostics and genetics to ensure accurate diagnosis of patients with rare diseases. Products Travere Therapeutics offers a variety of products and therapies in different stages of development. Here are some of the key products the company offers: · Isturisa: a medication for the treatment of Cushing's syndrome, a rare disease caused by overproduction of the hormone cortisol. · Re-PLAI: a medication for the treatment of nephrotic syndromes, a group of disorders caused by kidney dysfunction. · Enzyme Replacement Therapy (ERT): an approach to treating inherited metabolic disorders by administering missing enzymes. Conclusion Travere Therapeutics is an innovative company specializing in developing therapies for rare diseases. The company has a strong pipeline of drugs and the expertise to develop therapies for patients who are underserved by traditional medications. With a focus on research and diagnostics, the company has the potential to improve the lives of millions of patients with rare diseases. Travere Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Travere Therapeutics's EBIT

Travere Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Travere Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Travere Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Travere Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Travere Therapeutics stock

How much did Travere Therapeutics achieve in EBIT for the current year?

In the current year, Travere Therapeutics has achieved an EBIT of -272.7 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Travere Therapeutics.

How has the EBIT of Travere Therapeutics developed in recent years?

The EBIT of Travere Therapeutics has increased by -27.618% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Travere Therapeutics?

The EBIT of Travere Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Travere Therapeutics pay?

Over the past 12 months, Travere Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Travere Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Travere Therapeutics?

The current dividend yield of Travere Therapeutics is .

When does Travere Therapeutics pay dividends?

Travere Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Travere Therapeutics?

Travere Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Travere Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Travere Therapeutics located?

Travere Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Travere Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Travere Therapeutics from 8/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/25/2024.

When did Travere Therapeutics pay the last dividend?

The last dividend was paid out on 8/25/2024.

What was the dividend of Travere Therapeutics in the year 2023?

In the year 2023, Travere Therapeutics distributed 0 USD as dividends.

In which currency does Travere Therapeutics pay out the dividend?

The dividends of Travere Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Travere Therapeutics

Our stock analysis for Travere Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Travere Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.